Top Industry Leaders in the Dysfunctional Uterine Bleeding Market
Latest Dysfunctional Uterine Bleeding Companies Update
Myovant's Ormeloxifene (SER-120) Phase 3 Trials is conducting two Phase 3 trials (MUSE 1 and MUSE 2) evaluating the efficacy and safety of Ormeloxifene (SER-120) for the treatment of DUB caused by fibroids. Positive results could significantly impact the market by offering a non-hormonal therapy option.
Minerva Surgical's Sonata® System received FDA approval for its Sonata® System, a minimally invasive device for endometrial ablation used in the treatment of heavy menstrual bleeding and DUB. This technology offers an alternative to traditional hysterectomy for some patients.
List of Dysfunctional Uterine Bleeding Key Companies in the Market
- Braun Melsungen AG (Germany)
- Hologic Inc. (U.S.)
- Karl Storz Gmbh & Co. KG (Germany)
- Medgyn Products Inc.
- Olympus (Japan)
- Richard Wolf GmbH (Germany)
- Stryker (U.S.)
- Xion Medical GmbH (Germany)
- Cadila Pharmaceuticals Ltd. (India)
- Torrent Phamraceuticals (India)